Outcome analysis of 49 cases of fungal infections in patients with hematologic malignancy after amphotericin B treatment

Objective To analyze the efficacy and safety of amphotericin B in the treatment of invasive fungal infections in pa- tients with hematologic malignancy.Methods Patients with hematologic malignancy were given amphotericin B, 0.5-1.0 mg/kg per day for 10-6t days (median duration of 26 days).The clinical findings of symptoms and signs, hepatic and renal function tests and the results of electrolytes were reviewed on Day 7.Results The overall clinical efficacy rate of amphotericin B was 56.7%, and fungal elimination rate was 42.4%.The incidence of various adverse events ranged from 3.6% to 24.5%.The most common adverse events were systemic reactions like rigors, chills, and fever after amphotericin infusion, hypokalemia, gastrointestinal reaction, renal impairment, hepatic impairment and phlebitis.Conclusions Amphotericin B is still a highly ac- tive, broad-spectrum antifungal agent, though the adverse events are frequently reported.However, it may be well-tolerated in most patients if it is administered properly, and the side effects are managed appropriately.